The aim of this study was to evaluate the levels of SIRT1 and SIRT2 in the serum of patients with the relapsing–remitting type of MS (RRMS), as well as their relationships with various aspects of MS-related disability. This evidence concerns the gene SIRT2 and myeloid sarcoma.